Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Novel assay may better detect urothelial carcinoma

Key clinical point: A novel urine-based assay improved detection of urothelial carcinoma, compared with urine cytology.

Major finding: The Urine Exfoliated Cells Copy Number Aberration Detector assay had significantly higher sensitivity than urine cytology (80.4% vs. 33.9%; P < .001) but similar specificity (94.9% vs. 100%; P = .49) for urothelial carcinoma detection.

Study details: A prospective, observational study with a discovery cohort of 190 patients (126 with urothelial carcinoma and 64 noncancer controls) and a validation cohort of 95 patients (56 with urothelial carcinoma and 39 noncancer controls).

Disclosures: The research was supported by various funding sources in China. The authors reported having no conflicts of interest.

Citation:

Zeng S et al. Clin Cancer Res. 2020 Oct 9. doi: 10.1158/1078-0432.CCR-20-0401.